Jayex Healthcare Limited delighted to announce that it has executed a Software Licence Agreement with Lifespot Health Limited under which it has been granted an exclusive licence for the United Kingdom and a non-exclusive licence for Australia and New Zealand. The Software Licence Agreement will grant the Company the rights to market and sell Lifespot Health's existing BodyTel software platform and integrated Bluetooth technology products and services along with all future telehealth products and services developed. Both Jayex and Lifespot Health recognise the importance of providing remote monitoring capacity to GP clinics in a post COVID-19 world. The Company is looking forward to integrating the BodyTel capability into the Jayex Connect Platform enhancing the capacity for the 20,000+ GP's in the Jayex UK ecosystem to care for their patients. Under the Licence Agreement, Lifespot Health has granted the Company an exclusive licence for the United Kingdom and a non-exclusive licence for Australia and New Zealand, to market and sell Lifespot Health's existing developed BodyTel software platform and integrated Bluetooth technology products and services as well as future telehealth products and services developed during the term of the agreement. The BodyTel software platform and integrated Bluetooth technologies comprise medical diagnostic and monitoring technology and digitally enabled drug delivery systems to combine sensor technology with self- learning algorithms allowing patients to monitor chronic diseases and critical conditions with their smartphones. The Company looks forward to working collaboratively with Lifespot Health in pursing this exciting opportunity in the rapidly developing global medical technology market.